Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics
    Dr. Patrik De Haes, CEO
    Tel: +32-16-75-13-10
    patrik.dehaes@thrombogenics.com

    Chris Buyse, CFO
    Tel: +32-16-75-13-10
    chris.buyse@thrombogenics.com

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren
    Tel: +44-(0)207-638-95-71
    amber.bielecka@citigatedr.co.uk'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 Results from a Phase ... and its ability to reduce the size of melanoma ... published in the Journal of Clinical Oncology. , ... IIIB, IIIC and IV melanoma, a potentially fatal form ... was to evaluate the safety and efficacy of the ...
(Date:5/28/2015)... DUBLIN , May 28, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/7k46bt/therapeutic_drug ) has announced the addition of ... Monitoring - Technologies, Markets, and Companies" ... http://photos.prnewswire.com/prnh/20130307/600769) , This report deals ... specialty, aimed at improving patient care by ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) has announced the addition ... Testing services - Global Forecast to 2020" report ... market is estimated to be worth around $2.5 billion ... during the forecast period of 2014 to 2020 ... protein consumption, increasing adoption of advanced genetic technologies for ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation (the ... has received commitments from two institutional healthcare investors to ... Company,s common stock in an at-the-market registered direct offering ... common stock. The Company entered into a ... the Company agreed to sell an aggregate of 3,000,000 ...
Breaking Biology Technology:Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Therapeutic Drug Monitoring Market 2015-2024 2Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3
... NAIAD Biodefense . MADISON - In an ... ones that could be used as biological weapons, scientists ... information technology company, SRA International, Inc. , to ... these infectious agents and their genomes. , ,The work ...
... CHICAGO People are more skeptical of advertising than ever ... growing presence of the Internet allows them to quickly sink ... the hands of customers, and a greater need for companies ... the conference, held June 12, and 13, suggested companies need ...
... MENOMONIE, Wis. The Northwest Wisconsin Manufacturing ... was recently honored by the United States ... for Standards and Technology in their 10th year ... ranked number one, with over 450 centers and branches ...
Cached Biology Technology:UW-Madison joins effort to build public pathogen bioinformatics database 2AD:TECH: Advertisers face harsh lessons at the hands of powerful consumers 2AD:TECH: Advertisers face harsh lessons at the hands of powerful consumers 3AD:TECH: Advertisers face harsh lessons at the hands of powerful consumers 4
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... This press release is available in French . ... Bouchard, adjunct professor at the Center for Interdisciplinary Research ... Universit du Qubec Montral and a researcher at ... the Department of Biological Sciences and a member of ...
... all fingers point to a European mollusk about the size ... the doughnut in southern Lake Michigan, much less the mollusk, ... research team first saw it in 1998. That,s because scientists ... any of the shipwreck-studded Great Lakes in winter. But NASA,s ...
... University have been awarded federal funds totaling more than ... acids on breast cancer development. The U.S. Department ... Dr. Elaine Hardman, associate professor in the Department of ... of Medicine, and Dr. Philippe Georgel, associate professor in ...
Cached Biology News:Manganese in drinking water: Study suggests adverse effects on children's intellectual abilities 2Manganese in drinking water: Study suggests adverse effects on children's intellectual abilities 3Death of the 'doughnut' 2Death of the 'doughnut' 3Marshall University researchers awarded more than $1 million for breast cancer studies 2Marshall University researchers awarded more than $1 million for breast cancer studies 3